作者用一种新的皮质类固醇吸入制剂 Budesonide(Bud)对依赖皮质激素性哮喘患者进行了治疗观察,60例研究对象均为每日服强的松≥10mg 最少已服用3个月依赖皮质激素的患者,全部为门诊病人且均多次试图减少口服激素量而失败,60例病人中仅45例完成了51周的 Bud 治疗。在观察研究期间除β_2受体兴奋剂及每日服强的松外,其它抗喘治疗保持固定。当 Bud 治疗开始时二丙酸氯地米松(BDP)即停用。 The authors used a new corticosteroid inhalation preparation, Budesonide (Bud), to treat patients with glucocorticoid-induced asthma. 60 subjects were prednisone ≥ 10 mg daily for at least 3 months and were dependent on corticosteroids Patients, all outpatient and failed to reduce the amount of oral hormone many times, only 45 of 60 patients completed 51 weeks of Bud treatment. Other anti-asthmatic therapies remained fixed except during beta 2 agonists and daily prednisone during the study period. When Bud therapy begins beclomethasone dipropionate (BDP) that is disabled.